3-Methoxy-6-propan-2-yloxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃类
• 英文名称: 3-Methoxy-6-propan-2-yloxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan
• 英文别名: 3-methoxy-6-propan-2-yloxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan
• 化学式: C₁₀H₁₈O₄
• 分子量: 202.25
• InChiKey: MLJWQRNANMHDMD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  36.9
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• [EN] MAP4K4 INHIBITORS<br/>[FR] INHIBITEURS DE MAP4K4
  申请人：IMPERIAL INNOVATIONS LTD

  公开号：WO2019073253A1

  公开（公告）日：2019-04-18

  This invention relates to pyrrolopyrimidine comprising compounds that may be useful as inhibitors of Mitogen-activated Protein Kinase Kinase Kinase Kinase-4 (MAP4K4). The invention also relates to the use of these pyrrolopyrimidine comprising compounds, for example in a method of treatment. There are also provided processes for producing compounds of the present invention and method of their use. In particular, the present invention relates to compounds of formula (I).

  这项发明涉及含有吡咯吡嘧啶的化合物，这些化合物可能作为丝裂原活化蛋白激酶激酶激酶激酶-4（MAP4K4）的抑制剂而有用。该发明还涉及利用这些含有吡咯吡嘧啶的化合物，例如在治疗方法中的使用。还提供了生产本发明化合物的方法以及它们的使用方法。具体而言，本发明涉及式（I）的化合物。
• LIQUID-CRYSTALLINE MEDIUM
  申请人：MERCK PATENT GMBH

  公开号：US20190292460A1

  公开（公告）日：2019-09-26

  Liquid-crystalline media comprising one or more compounds of formula D and one or more compounds selected from the group of compounds of formulae I, II and III, in which the occurring groups and parameters have the meanings defined in claim 1 , and to high-frequency components comprising these media, especially microwave components for high-frequency devices, such as devices for shifting the phase of microwaves, tunable filters, tunable metamaterial structures, and electronic beam steering antennas (e.g. phased array antennas).
• MAP4K4 INHIBITORS
  申请人：IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE

  公开号：US20200339583A1

  公开（公告）日：2020-10-29

  This invention relates to pyrrolopyrimidine comprising compounds that may be useful as inhibitors of Mitogen-activated Protein Kinase Kinase Kinase Kinase-4 (MAP4K4). The invention also relates to the use of these pyrrolopyrimidine comprising compounds, for example in a method of treatment. There are also provided processes for producing compounds of the present invention and method of their use. In particular, the present invention relates to compounds of formula (I).